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Introduction: The potential to accurately quantify epidermal growth 
factor receptor (EGFR) mutations in plasma from non–small-cell 
lung cancer patients would enable more rapid and more frequent 
analyses to assess disease status; however, the utility of such analyses 
for clinical purposes has only recently started to explore.
Methods: Plasma samples were obtained from 69 patients with 
EGFR-mutated tumors and 21 negative control cases. EGFR muta-
tions in plasma were analyzed by a standardized allele-specific poly-
merase chain reaction (PCR) test and ultra-deep next-generation 
sequencing (NGS). A semiquantitative index (SQI) was derived from 
dilutions of known EGFR mutation copy numbers. Clinical responses 
were evaluated by Response Evaluation Criteria in Solid Tumors 1.1 
criteria and expressed as percent tumor shrinkage.
Results: The sensitivity and specificity of the PCR test and NGS 
assay in plasma versus tissue were 72% versus 100% and 74% versus 
100%, respectively. Quantitative indices by the PCR test and NGS 
were significantly correlated (p < 0.001). EGFR testing at baseline 
and serially at 4 to 60 days during tyrosine kinase inhibitor therapy 
revealed a progressive decrease in SQI, starting from day 4, in 95% 
of cases. The rate of SQI decrease correlated with percent tumor 
shrinkage at 2 months (p < 0.0001); at 14 days, it was more than 
50% in 70% of patients (rapid responders). In two patients with slow 
response, an early increase in the circulating levels of the T790M 
mutation was observed. No early T790M mutations were seen in 
plasma samples of rapid responders.
Conclusions: Quantification of EGFR mutations from plasma with a 
standardized PCR test is feasible. To our knowledge, this is the first 
study showing a strong correlation between the EGFR SQI in the first 
days of treatment and clinical response with relevant implications for 
patient management.
Key Words: EGFR mutations, NSCLC, Plasma, Next-generation 
sequencing, Predictive medicine.
(J Thorac Oncol. 2015;10: 1437–1443)
Assessment of epidermal growth factor receptor (EGFR) mutations in non–small-cell lung cancer (NSCLC) 
patients is mandatory for proper treatment choice and is usu-
ally performed on tissue or cytological samples.1–4 However, 
the lack of neoplastic tissue may be a critical issue preventing 
molecular characterization. For example, in the phase 3 IPASS 
study, only 42% of the patients had biopsied tissue suitable 
for molecular testing, and in the phase 3 INTEREST study, 
only 31% had adequate tissue.5,6 Several reports indicate 
that EGFR mutations can be detected in plasma or serum of 
NSCLC patients.7–12 Although mutation analysis in tissue has 
been required as a reflection of disease state, the development 
and validation of analytical tools using plasma as the primary 
material has been pursued only recently.
Neoplastic tissue remains the definitive standard for molec-
ular analysis, and available in vitro diagnostic assays for clinical 
application have been validated using tumor tissue. However, the 
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potential for analyzing plasma to assess disease mutation status 
is attractive for several reasons, including noninvasive sampling 
compared with biopsy, enabling increased sampling frequency, 
testing in critically ill patients, and testing at diagnosis when 
tumor samples are unavailable. Blood collection is less invasive 
than tissue sampling, can be used where tissue specimens are 
limited, can be repeated frequently over time, or may be the only 
option for critically ill patients. Finally, plasma testing may reflect 
overall disease status compared with a conventional, small sam-
ple from a single tumor site. During treatment, plasma analysis 
could reveal the emergence of EGFR treatment–resistance muta-
tions, possibly well in advance of clinical progression.
As DNA analytical methods have become more sensi-
tive, attempts to develop methods to assess tumor mutation 
status by evaluating patient plasma samples are now being 
pursued. This study evaluated the ability to quantify the pres-
ence of EGFR-mutated alleles in plasma of NSCLC patients 
for early prediction of response to tyrosine kinase inhibitor 
(TKI) therapy. We compared two different methods for quan-
tifying EGFR mutations in NSCLC patient plasma samples, 
specifically, the cobas® EGFR Mutation Test (“PCR test”) and 
ultra-deep next-generation sequencing (NGS). We then quan-
titatively monitored EGFR mutations in plasma samples from 
an independent prospective series of patients, at baseline and 
serially, during the first days of treatment with TKIs. EGFR 
mutation data were compared with clinical response.
PATIENTS AND METHODS
Patients
Two hundred and three peripheral blood samples were 
collected from 85 subjects including: (1) 42 NSCLC patients 
harboring EGFR mutations in primary tumor tissue, enrolled 
in the TRIGGER trial (see below), where plasma samples were 
collected at baseline, before first-line treatment with erlotinib 
(Tarceva; Genentech), and immediately after progression; (2) 
27 previously untreated stage IIIB-IV NSCLC patients, carrying 
EGFR mutations in tumor specimens, for whom plasma was col-
lected at baseline and serially at 4 to 60 days during erlotinib ther-
apy; and (3) 21 control cases, comprising 10 breast carcinoma 
patients negative for EGFR mutations and 11 healthy donors.
TRIGGER is a phase II, open-label study of TaRceva® 
(erlotinib) treatment In chemonaive  patients with locally 
advanced or metastatic non-small-cell lunG cancer who pres-
ent activatinG mutations in the tyrosine kinase domain of 
the Epidermal growth factor Receptor; clinical Trials.gov 
identifier: NCT01378962. The main objective of the study 
was to evaluate the efficacy of erlotinib (150 mg) in terms of 
12-month progression-free survival. An exploratory objective 
of the TRIGGER study was to evaluate the correlation between 
EGFR testing in tumor biopsies and plasma samples at base-
line and tumor progression. Study details will be described in 
a future publication.
Written informed consent was obtained from all 
patients under study. Approval from independent regional 
Ethics Committees was obtained for all patients. The study 
was conducted in accordance with the precepts of the Helsinki 
Declaration.
Blood Sample Collection and DNA Extraction
At each collection, two blood samples containing 5 ml 
were collected in BD VACUTAINER PPT K2EDTA tubes 
(BD Diagnostics, Buccinasco (Milan), Italy) and subjected 
locally to plasma separation, within 30 minutes, using a 
shared protocol. After centrifugation at 1000 rpm for 15 min-
utes, the plasma was aliquoted and stored at −80°C until DNA 
extraction by the Center of Predictive Molecular Medicine 
(University-Foundation, Chieti, Italy). DNA was extracted 
from 4 ml of plasma using the cobas® cfDNA Sample 
Preparation kit (under development by Roche Molecular 
Systems, Pleasanton, CA), according to the manufacturer’s 
instructions. DNA was recovered in 200 μl of elution buffer. 
The DNA amount was not measured to avoid loss of material. 
Half of the volume was used for PCR assay and the other half 
for ultra-deep NGS analysis.
Assessment of EGFR Mutations from 
Tissue Samples and Plasma DNA
EGFR mutation analysis in tissue samples at the time of 
diagnosis was conducted in the collaborating clinical centers by 
Sanger sequencing or other conventional techniques and con-
firmed by Sanger sequencing. The plasma test used in this study 
is an allele-specific polymerase chain reaction (PCR) assay 
designed to detect 41 EGFR mutations: G719A/C/S in exon 18; 
29 deletions in exon 19; S768I, T790M, five insertions in exon 
20; and L858R in exon 21. Analysis was confirmed by nega-
tive and positive controls contained in the kit. The PCR reac-
tions were run on the cobas® z 480 analyzer with EGFR Blood 
Analysis Package Software (in development, Roche Molecular 
Systems, Pleasanton, CA). A semiquantitative index (SQI) was 
created to reflect a trend for the proportion of mutated versus 
wild-type copies of the EGFR gene. The SQI was derived from 
a dilution series containing known copy numbers of mutated 
EGFR and a fixed amount of wild-type EGFR, with the wild-
type DNA serving as an internal control during real-time PCR. 
The SQI is reported as an automated result from the cobas® z 
480 software when an EGFR mutation is detected in ctDNA. A 
positive correlation of the SQI to copy number and reproduc-
ibility of the data was demonstrated by linearity studies with 
spike-in control mutations (data not shown).
Ultra-deep NGS was performed as follows. DNA fusion 
primers containing genome-specific sequences, along with one 
of seven distinct 10-base pair multiplex identifier sequences, 
and sequencing adapters were used to amplify specific regions 
of exons 18, 19, 20, and 21 of the EGFR gene (NM_005228.3), 
as previously described, and were used to distinguish samples 
run on the same plate.13 Different strategies to maximize sen-
sitivity and avoid cross-contamination were adopted as previ-
ously described.14 Processed and quality-filtered reads were 
analyzed with the GS Amplicon Variant Analyzer software 
version 2.7 (454 Life Sciences). NGS analysis was repeated in 
cases with mutations in less than 1% of the DNA molecules. 
The percentage of the mutant allele in the whole number of 
sequenced molecules was used as a quantitative index.
The variables measured in the study were investigated 
for association by regression analysis and independent sam-
ples two-sided t test. A p value less than 0.05 was considered 
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as significant. Statistical analyses were performed using SPSS 
version 22 (SPSS, Chicago, IL).
RESULTS
Plasma Samples
A total of 203 plasma samples from 69 patients and 21 
control cases were examined. The TRIGGER blood samples 
at baseline and progression were analyzed by both PCR and 
ultra-deep NGS, two different techniques which allow to 
quantify EGFR mutations in plasma. In an independent pro-
spective series, monitoring of the EGFR SQI was performed 
by the PCR test at baseline and serially during the first days of 
TKI treatment.
EGFR Mutation Detection by PCR
EGFR mutation analysis in tissue samples of the 42 
NSCLC patients enrolled in the prospective TRIGGER trial 
showed an exon 19 deletion in 31 cases (74%) and an L858R 
point mutation in exon 21 in 11 cases (26%) (Supplementary 
Table S1, Supplemental Digital Content 1, http://links.lww.
com/JTO/A863). Plasma samples were collected from these 
42 patients before treatment with erlotinib. Plasma samples 
were also obtained after progression in 15 patients during the 
12-month follow-up. With baseline plasma, 30 cases (71%) 
were mutated with the EGFR PCR test and corresponded 
exactly with mutations present in matching tissue samples. 
At progression, 11 of 15 plasma samples (73%) showed the 
same sensitizing mutation detected in tumor tissues. In five of 
these 11 cases (45%), the T790M mutation was concomitantly 
detected. No mutations were present in the 21 control cases. 
Overall, the sensitivity and specificity of the PCR test were 
72% and 100%, respectively.
Mutation Detection by Ultra-Deep NGS
Ultra-deep NGS was conducted with a mean cover-
age of 20,230 ± 1410 sequences per sample. In the series of 
42 patient plasma samples at baseline, 31 cases (74%) were 
mutated, with mutations corresponding to those in the match-
ing tumor sample. Eleven of the 15 plasma samples (73%) at 
progression showed the same sensitizing mutation detected at 
baseline. No mutations were detected in the 21 control cases. 
The ultra-deep NGS assay showed a sensitivity of 74% and a 
specificity of 100%. The T790M mutation was detected in the 
five plasma samples that were also positive for this mutation by 
the PCR test (Supplementary Table S1, Supplemental Digital 
Content 1 [http://links.lww.com/JTO/A863] and Table 1).
EGFR Mutation Detection: PCR 
versus Ultra-Deep NGS
Table 1 reports the quantification of EGFR muta-
tions in plasma samples from the TRIGGER study, by the 
PCR test and ultra-deep NGS, in EGFR exons 19 and 21 at 
baseline, and for the T790M mutation in exon 20 at progres-
sion. The results indicate a strong exponential relationship 
between the PCR test and ultra-deep NGS indexes (R2 > 95%; 
p < 0.0001; Fig. 1). The PCR test is based on a mutant-specific 
PCR amplification, resulting in an enrichment of mutant mol-
ecules, whereas the ultra-deep NGS assay was performed with 
conventional PCR.
Quantification data from ultra-deep NGS show that 18 
of the 34 mutations (53%) detected in plasma were present in 
less than 1% of the reads, indicating that sensitive mutation 
detection techniques must be used to screen plasma samples 
for EGFR mutations. The PCR test was also extremely sensi-
tive, detecting mutations present in as low as 0.02% of the 
molecules (Table 1).
In 12 plasma samples (29%) from TRIGGER patients 
at baseline, the PCR assay failed to find EGFR mutations. 
Results from two cases analyzed by NGS were in agree-
ment with tissue samples but were not detectable by PCR 
TABLE 1.  Comparison of Quantification Data by PCR versus 
Ultra-Deep NGS
Case No.
Type of  
Mutation NGS PCR
21 Exon 19 Del 0.02 5.99
23 Exon 19 Del 0.05 8.29
6 Exon 19 Del 0.06 8.49
10 Exon 19 Del 0.06 8.62
4 Exon 19 Del 0.07 8.91
22 Exon 19 Del 0.24 9.50
35 Exon 19 Del 0.27 9.55
37 Exon 19 Del 0.29 10.04
42 Exon 19 Del 0.33 10.20
15 Exon 19 Del 0.80 12.07
31 Exon 19 Del 0.81 12.44
19 Exon 19 Del 0.88 12.45
25 Exon 19 Del 0.98 13.59
2 Exon 19 Del 1.51 13.74
8 Exon 19 Del 1.57 13.91
32 Exon 19 Del 0.81 13.97
30 Exon 19 Del 1.68 14.86
13 Exon 19 Del 3.05 15.82
5 Exon 19 Del 3.84 16.18
28 Exon 19 Del 6.42 16.88
16 Exon 19 Del 45.29 21.58
20 Exon 19 Del 55.83 20.62
26 Exon 19 Del 72.06 19.88
17 L858R 0.21 7.4
18 L858R 0.22 8.04
36 L858R 1.37 10.74
14 L858R 1.76 11.48
7 L858R 31.38 14.39
38 L858R 41.17 15.29
31 T790M 0.16 11.34
28 T790M 0.91 13.11
26 T790M 2.46 14.57
20 T790M 3.55 14.70
7 T790M 24.5 17.08
NGS, next-generation sequencing; PCR, polymerase chain reaction.
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testing (an extremely rare type of exon 19 deletion, p.E747_
A749del and the L861Q mutation) (Supplementary Table 
S1, Supplemental Digital Content 1, http://links.lww.com/
JTO/A863); in 11 of TRIGGER plasma samples (26%) at 
baseline, the ultra-deep NGS analysis could not detect an 
EGFR mutation. In one of these cases identified with PCR 
(patient number 23), an L858R mutation was observed in a 
very low proportion of the molecules (SQI, 4.99), in keep-
ing with tissue data (Supplementary Table S1, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A863). Overall, 
by using the two different approaches, 32 of 42 cases (76%) 
in the TRIGGER series were found to carry an EGFR muta-
tion in plasma.
Plasma Monitoring of EGFR Mutations
To assess the potential clinical utility of monitoring 
EGFR mutations in plasma at initiation of treatment with 
TKIs, we assessed EGFR mutations in plasma samples of 
27 previously untreated patients carrying EGFR mutations 
in their primary tumors at baseline and serially at 4, 8, 13, 
18, 25, 35, and 60 days during TKI therapy. Seven of these 
patients (26%) were negative at baseline. SQI curves indi-
cating the amount of mutant EGFR in plasma of 20 patients 
during the first days of treatment are reported in Figure 2. 
With serial testing, the EGFR SQI demonstrated a progres-
sive decrease starting from day 4 of therapy in 95% of cases. 
After 4 days of treatment, we observed an average percent 
decrease of 13.5%. At 8 days, the average percent decrease 
was 41.6% and at 14 days 63.5%. In all but two patients, 
plasma samples became negative for mutant EGFR alleles 
in a time range of 8 to 60 days (mutation clearing time). 
The rate of SQI decrease was greater than 50% at 14 days 
in 14 patients (70%) (rapid responders) and lower than 50% 
at 14 days in six patients (30%) (slow responders) (Fig. 3) 
and was directly correlated with PTS at 2 months, evalu-
ated by Response Evaluation Criteria in Solid Tumors 1.1 
criteria (Table 2). The mean percentage of tumor shrinkage 
(PTS) was 59.1 ± 1.8 in the rapid responders and 18.3 ± 3.7 in 
the slow responders (p < 0.0001). An EGFR mutation in the 
plasma of two slow responders was not completely cleared 
by TKI treatment. In these two patients, the T790M mutation 
was unexpectedly detected very early after initiating ther-
apy, at 35 days, and further increased in the following days 
(Fig. 3). These cases were defined as early resistant.
DISCUSSION
The aim of this study was to evaluate the feasibility of 
finding EGFR mutations in plasma and to test whether deter-
mining mutant EGFR levels during the first days of treatment 
with EGFR TKIs may reflect clinical response. SQI values for 
EGFR mutations in plasma were generated by the PCR test. 
Results were confirmed by ultra-deep NGS we have recently 
developed and applied to detect rare EGFR mutations in cyto-
logical samples and circulating tumor cells.13,15
Two quantification methods were tested on a series of 42 
EGFR-positive NSCLC patients enrolled in the multicenter, 
prospective TRIGGER trial and 21 negative controls. Plasma 
samples were collected at baseline and immediately after pro-
gression. The sensitivity and specificity of EGFR detection in 
plasma versus tissue were, respectively, 72% and 100% for the 
PCR test and 74% and 100% for ultra-deep NGS. The con-
cordance rate between the two assays was 95%. The detection 
sensitivity at baseline and progression were very similar (71% 
and 73% by the PCR test and 74% and 73% by ultra-deep 
NGS, respectively). Our results are in keeping with published 
data.8,9,11,16
Quantitative results reported in Table 2 and Figure 2 
indicate a strong correlation between data obtained by PCR 
and ultra-deep NGS. This can be ascribed to the fact that 
the PCR assay uses mutation-specific primers that greatly 
enhance the detection of mutated alleles, whereas the ultra-
deep NGS assay is based on deep sequence analysis of normal 
and mutant EGFR molecules amplified by intronic primers.
EGFR quantification data in plasma revealed that the 
percentage of mutated alleles in the series of patients analyzed 
varied from 0.02% to 55% as revealed by ultra-deep NGS. 
Remarkably, mutated EGFR represented less than 1% of the 
total EGFR DNA in plasma for about 50% of the patients. 
Clearly, highly sensitive techniques must be used to detect low 
levels of mutant DNA. We have previously shown, through a 
FIGURE 1.  Detection of EGFR mutations with PCR versus ultra-deep NGS. Data were plotted for deletion in exon 19 (23 
patients) (A), L858R in exon 21 (six patients) (B), or T790M in exon 20 (five patients) (C). NGS, next-generation sequencing; 
PCR, polymerase chain reaction.
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series of dilution experiments, that ultra-deep NGS is one of 
the most sensitive methods for detecting EGFR mutations.13,15
Two different quantification approaches showed that 
the PCR test designed for detecting EGFR mutations is an 
extremely sensitive assay. PCR-based analyses such as this test 
are preferable to ultra-deep NGS in clinical practice because 
they are faster, easier, cheaper, and less prone to cross-con-
tamination. However, because PCR-based assays use primers 
with known mutations to amplify mutated EGFR sequences, 
this approach will miss uncommon genetic alterations.
In an independent prospective series of NSCLC patients 
carrying EGFR mutations in tumor tissue and subjected to 
first-line treatment with EGFR TKIs, we show for the first 
time that accurate quantification of EGFR mutations, rela-
tive to NGS, in plasma may be useful for early prediction of 
clinical response. In 95% of the cases, we observed a progres-
sive decrease of the EGFR SQI starting from the fourth day 
of treatment, with an average decrease of 63.5% at 14 days 
after initiation of treatment. Patients with a rapid versus slow 
decrease in mutant EGFR levels at 14 days were identified by 
using a cutoff of 50%. In rapid responders, a rapid decrease in 
mutated plasma EGFR DNA was associated with high levels 
of tumor shrinkage at 2 months. In slow responders, an attenu-
ated decrease in mutated plasma EGFR DNA was associated 
with a lower PTS at 2 months. Two slow responders did not 
reach mutation clearance as measured by the PCR test, and 
an early increase in the circulating levels of the T790M muta-
tion was observed. No T790M mutations were seen in serial 
plasma samples of the rapid responders. We therefore spec-
ulate that slow responders are more prone to develop early 
resistance. However, further clinical validation is required to 
assess the long-term impact of TKI treatment on rapid ver-
sus slow responders relative to progression-free and overall 
survival.
Our finding that mutant allele frequency drop soon after 
therapy is intriguing. As circulating tumor DNA could come 
from breakdown of tumor cells, we would have expected that 
the EGFR SQI would initially increase and then decrease as 
the ctDNA is cleared. Our experimental data clearly indicate 
a different situation, at least starting from the fourth day of 
treatment. A possible explanation is that the amount of circu-
lating DNA in blood depends mainly on the amount of tumor 
cells released in the bloodstream that could decrease under 
treatment. Necrotic or apoptotic cells could only be marginally 
involved in the process, and they could be locally removed by 
the immune system. However, we cannot exclude the possibil-
ity of an increment of mutant EGFR in plasma immediately 
after therapy.
CONCLUSION
In conclusion, our data suggest that quantification of 
mutant EGFR in plasma DNA in the first days of treatment may 
FIGURE 2.  Quantification of mutated 
EGFR DNA from plasma of 20 patients 
by the PCR test after initiation of EGFR 
TKI therapy. A, Rapid responders. 
These 14 patients showed an EGFR 
SQI of 50% or greater at 14 days 
after initiating TKI treatment. B, Slow 
responders. These six patients showed 
an EGFR SQI below 50% at 14 days 
after initiating TKI treatment. The top 
two lines (turquoise and light green) 
are from two patients who developed 
T790M mutation. PCR, polymerase 
chain reaction; SQI, semiquantitative 
index; TKI, tyrosine kinase inhibitor.
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represent an early predictive parameter of clinical response. 
This new method of detecting EGFR mutation status could have 
important clinical applications, in that it could (1) complement 
or replace more expensive and invasive methods to assess 
response in TKI-treated patients; (2) allow early detection 
of the T790M mutations for possible changes to therapy; (3) 
represent a new way to compare the effectiveness of different 
drugs on EGFR-mutated tumors; and (4) be an additional tool 
to evaluate the best treatment regimen for patients.
With the strong correlation between EGFR SQI in 
plasma and clinical outcome, this study opens the way to 
prospectively design clinical trials to confirm these data and 
evaluate the diagnostic value of this test.
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